ATE448781T1 - Methoden zur hemmung der aktivität der osteoklasten - Google Patents

Methoden zur hemmung der aktivität der osteoklasten

Info

Publication number
ATE448781T1
ATE448781T1 AT00950797T AT00950797T ATE448781T1 AT E448781 T1 ATE448781 T1 AT E448781T1 AT 00950797 T AT00950797 T AT 00950797T AT 00950797 T AT00950797 T AT 00950797T AT E448781 T1 ATE448781 T1 AT E448781T1
Authority
AT
Austria
Prior art keywords
methods
trance
disclosed
osteoclasts
activity
Prior art date
Application number
AT00950797T
Other languages
English (en)
Inventor
Ramachandran Murali
Mark Greene
Masahiko Kinosaki
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE448781T1 publication Critical patent/ATE448781T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00950797T 1999-07-28 2000-07-28 Methoden zur hemmung der aktivität der osteoklasten ATE448781T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14609499P 1999-07-28 1999-07-28
PCT/US2000/020502 WO2001008677A1 (en) 1999-07-28 2000-07-28 Methods of inhibiting osteoclast activity

Publications (1)

Publication Number Publication Date
ATE448781T1 true ATE448781T1 (de) 2009-12-15

Family

ID=22515834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00950797T ATE448781T1 (de) 1999-07-28 2000-07-28 Methoden zur hemmung der aktivität der osteoklasten

Country Status (7)

Country Link
EP (1) EP1207873B1 (de)
JP (1) JP4790179B2 (de)
AT (1) ATE448781T1 (de)
AU (2) AU778190B2 (de)
CA (2) CA2647796A1 (de)
DE (1) DE60043346D1 (de)
WO (1) WO2001008677A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221963A4 (de) * 1999-07-28 2006-03-22 Univ Pennsylvania Methoden zur hemmung der osteoclastogenese
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
ATE399790T1 (de) 2001-07-03 2008-07-15 Febit Biotech Gmbh Zweistufige schutzgruppen für die synthese von biopolymeren
AU2008259342B2 (en) * 2007-06-04 2014-07-10 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
JP5191487B2 (ja) 2007-06-05 2013-05-08 オリエンタル酵母工業株式会社 新しい骨量増加薬
RU2010150688A (ru) * 2008-05-13 2012-06-20 Ашок Ранганат ШЕЛАР (IN) Медицинские применения гидразонов бензойной кислоты, синтезированных на основе стероидного тигогенина
WO2014062631A1 (en) * 2012-10-15 2014-04-24 Iowa State University Research Foundation, Inc. Polyisocyanates from fused bicyclic polyols and polyurethanes therefrom
US10000503B2 (en) 2011-09-09 2018-06-19 Sumitomo Electric Industries, Ltd. Power supply system and connector
WO2014144342A1 (en) * 2013-03-15 2014-09-18 Pharmatrophix, Inc. Non-peptide bdnf neurotrophin mimetics
CA2901839A1 (en) 2013-03-15 2014-09-18 Pharmatrophix, Inc. Non-peptide bdnf neurotrophin mimetics
US9321803B2 (en) * 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
WO2015068156A1 (en) 2013-11-05 2015-05-14 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
US10077257B2 (en) 2015-04-06 2018-09-18 Iowa State University Research Foundation, Inc. Aziridinated triglycerides and polymers formed therefrom
US10392471B2 (en) 2015-05-14 2019-08-27 Iowa State University Research Foundation, Inc. Polymers and methods of making the same
EP3299382B1 (de) * 2015-05-20 2023-04-26 Osaka University Oligopeptid mit proinflammatorischer zytokinsekretionshemmender wirkung
JP7641695B2 (ja) 2017-03-28 2025-03-07 チルドレンズ ホスピタル メディカル センター ノロウイルスｓ粒子ベースのワクチンならびにその作製および使用方法
CN110229118B (zh) 2019-06-28 2021-03-02 深圳市三启药物开发有限公司 腙酰胺类衍生物及其在制备抗骨质疏松药物中的应用
CN111686116B (zh) * 2020-06-08 2021-05-04 广东省微生物研究所（广东省微生物分析检测中心） 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2003203A1 (de) * 1996-12-23 2008-12-17 Immunex Corporation Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
ATE412746T1 (de) * 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
JP4401025B2 (ja) * 1998-07-01 2010-01-20 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 分子間相互作用の腔誘導アロステリック修飾および同一の効果を持つ化合物の同定方法
CN1318105A (zh) * 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
EP1221963A4 (de) * 1999-07-28 2006-03-22 Univ Pennsylvania Methoden zur hemmung der osteoclastogenese

Also Published As

Publication number Publication date
JP2003505503A (ja) 2003-02-12
AU778190B2 (en) 2004-11-18
AU6384600A (en) 2001-02-19
AU2005200650A1 (en) 2005-03-10
AU2005200650B2 (en) 2007-11-15
CA2380007A1 (en) 2001-02-08
EP1207873A4 (de) 2006-04-12
CA2647796A1 (en) 2001-02-08
WO2001008677A8 (en) 2001-07-12
WO2001008677A1 (en) 2001-02-08
DE60043346D1 (de) 2009-12-31
EP1207873B1 (de) 2009-11-18
EP1207873A1 (de) 2002-05-29
JP4790179B2 (ja) 2011-10-12

Similar Documents

Publication Publication Date Title
ATE448781T1 (de) Methoden zur hemmung der aktivität der osteoklasten
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
ATE387912T1 (de) Transepikutane darreichungsform zur behandlung des restless leg syndroms
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
WO2004110302A3 (en) Methods of delivering anti-restenotic agents from a stent
DE60041147D1 (de) Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
Viana et al. Use of calcitonin in recalcitrant phantom limb pain complicated by heterotopic ossification
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties